1U.K.The following substances and products, namely:—
[F1(a)]
Acetyldihydrocodeine.
Amphetamine.
[F2Cannabinol]
[F2Cannabinol derivatives]
[F2Cannabis and cannabis resin]
F3...
Codeine.
F4. . .
Dihydrocodeine.
Ethylmorphine (3-ethylmorphine).
[F5Glutethimide.]
[F5Lefetamine.]
[F6Mecloqualone.]
[F6Methaqualone.]
[F7Methcathinone]
[F84–Methylmethcathinone]
F9...
[F10a-Methylphenethylhydroxylamine]
Methylphenidate.
[F6Methylphenobarbitone.]
Nicocodine.
[F11Nicodicodine (6-nicotinoyldihydrocodeine).]
Norcodeine.
[F12Pentazocine.]
Phenmetrazine.
Pholcodine.
[F13Propiram.]
[F7Zipeprol]
[F14(aa)Any compound (not being bupropion, cathinone, diethylpropion, pyrovalerone or a compound for the time being specified in sub–paragraph (a) above) structurally derived from 2–amino–1–phenyl–1–propanone by modification in any of the following ways, that is to say,
(i)by substitution in the phenyl ring to any extent with alkyl, alkoxy, alkylenedioxy, haloalkyl or halide substituents, whether or not further substituted in the phenyl ring by one or more other univalent substituents;
(ii)by substitution at the 3–position with an alkyl substituent;
(iii)by substitution at the nitrogen atom with alkyl or dialkyl groups, or by inclusion of the nitrogen atom in a cyclic structure.]
[F1(b)any 5,5 disubstituted barbituric acid.]
[F15(c)[2,3–Dihydro–5–methyl–3–(4–morpholinylmethyl)pyrrolo[1, 2, 3–de]–1,4–benzoxazin–6–yl]–1–naphthalenylmethanone.
3–Dimethylheptyl–11–hydroxyhexahydrocannabinol.
[9–Hydroxy–6–methyl–3–[5–phenylpentan–2–yl] oxy–5, 6, 6a, 7, 8, 9, 10, 10a–octahydrophenanthridin–1–yl] acetate.
9-(Hydroxymethyl)–6, 6–dimethyl–3–(2–methyloctan–2–yl)–6a, 7, 10, 10a–tetrahydrobenzo[c]chromen–1–ol.
Nabilone.
Any compound structurally derived from 3–(1–naphthoyl)indole or 1H–indol–3–yl–(1–naphthyl)methane by substitution at the nitrogen atom of the indole ring by alkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl or 2–(4–morpholinyl)ethyl, whether or not further substituted in the indole ring to any extent and whether or not substituted in the naphthyl ring to any extent.
Any compound structurally derived from 3–(1–naphthoyl)pyrrole by substitution at the nitrogen atom of the pyrrole ring by alkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl or 2–(4–morpholinyl)ethyl, whether or not further substituted in the pyrrole ring to any extent and whether or not substituted in the naphthyl ring to any extent.
Any compound structurally derived from 1–(1–naphthylmethyl)indene by substitution at the 3–position of the indene ring by alkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl or 2–(4–morpholinyl)ethyl, whether or not further substituted in the indene ring to any extent and whether or not substituted in the naphthyl ring to any extent.
Any compound structurally derived from 3–phenylacetylindole by substitution at the nitrogen atom of the indole ring with alkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl or 2–(4–morpholinyl)ethyl, whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent.
Any compound structurally derived from 2–(3–hydroxycyclohexyl)phenol by substitution at the 5–position of the phenolic ring by alkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl or 2–(4–morpholinyl)ethyl, whether or not further substituted in the cyclohexyl ring to any extent.]
Textual Amendments
F1Sch. 2 Pt. 2 para. 1(b) added by S.I. 1984/859, art. 2(3)
F2Words in Sch. 2 Pt. 2 para. 1(a) inserted (26.1.2009) by The Misuse of Drugs Act 1971 (Amendment) Order 2008 (S.I. 2008/3130), art. 2(2)(a)
F3Words in Sch. 2 Pt. 2 para. 1(a) deleted (29.1.2004) by The Misuse of Drugs Act 1971 (Modification) (No. 2) Order 2003 (S.I. 2003/3201), art. 2(3)
F4Word repealed by S.I. 1985/1995, art. 2(2)(a)
F5Word inserted by S.I. 1985/1995, art. 2(2)(b)
F6Word inserted by S.I. 1984/859, art. 2(3)
F7Words in Sch. 2 Pt. 2 para. 1(a) inserted (1.5.1998) by S.I. 1998/750, art. 2(3)
F8Word in Sch. 2 Pt. 2 para. 1(a) inserted (16.4.2010) by The Misuse of Drugs Act 1971 (Amendment) Order 2010 (S.I. 2010/1207), art. 2(a)
F9Word in Sch. 2 Pt. 2 para. 1(a) repealed (18.1.2007) by The Misuse of Drugs Act 1971 (Amendment) Order 2006 (S.I.2006/3331), art. 2(2)
F10Word in Sch. 2 Pt. 2 para. 1(a) inserted (1.2.2002) by S.I. 2001/3932, art. 2(3)
F11Words inserted by S.I. 1973/771, art. 2
F12Word inserted by S.I. 1985/1995, art. 2(2)(c)
F13Word inserted by S.I. 1973/771, art. 2
F14Sch. 2 Pt. 2 para. 1(aa) inserted (16.4.2010) by The Misuse of Drugs Act 1971 (Amendment) Order 2010 (S.I. 2010/1207), art. 2(b)
F15Sch. 2 Pt. 2 para. 1(c) inserted (23.12.2009) by The Misuse of Drugs Act 1971 (Amendment) Order 2009 (S.I. 2009/3209), art. 2(2)(a)
2U.K.Any stereoisomeric form of a substance for the time being specified in paragraph 1 of this Part of this Schedule.
[F162A.U.K.Any ester or ether of cannabinol or of a cannabinol derivative [F17or of a substance for the time being specified in paragraph 1(c) of this Part of this Schedule.] .]
Textual Amendments
F16Sch. 2 Pt. 2 para. 2A inserted (26.1.2009) by Misuse of Drugs Act 1971 (Amendment) Order 2008 (S.I. 2008/3130), arts. 1(1), 2(2)(b)
F17Words in Sch. 2 Pt. 2 para. 2A inserted (23.12.2009) by Misuse of Drugs Act 1971 (Amendment) Order 2009 (S.I. 2009/3209), arts. 1, 2(2)(b)
3U.K.Any salt of a substance for the time being specified in paragraph 1 [F18, 2 or 2A] of this Part of this Schedule.
Textual Amendments
F18Words in Sch. 2 Pt. 2 para. 3 substituted ( 26.1.2009 ) by The Misuse of Drugs Act 1971 (Amendment) Order 2008 (S.I. 2008/3130), art. 2(2)(c)
4U.K.Any preparation or other product containing a substance or product for the time being specified in any of paragraphs 1 to 3 of this Part of this Schedule, not being a preparation falling within paragraph 6 of Part I of this Schedule.